Hemolysis testing for traditional Chinese medicine (TCM) is a mandatory safety evaluation that determines whether herbal preparations, particularly injectable formulations, cause the destruction of red blood cells. This technical guide explains the principles, sample types, test methods, acceptance criteria, and regulatory requirements of the TCM hemolysis test, serving as a practical reference for pharmaceutical laboratories and manufacturers.
Technical Overview
Hemolysis testing is a critical preclinical safety assessment designed to evaluate whether a pharmaceutical substance causes the rupture of red blood cells (erythrocytes) and the subsequent release of hemoglobin into the surrounding medium. For traditional Chinese medicine, this test carries particular importance because many TCM preparations contain chemically complex constituents, including saponins, tannins, flavonoids, alkaloids, and organic acids, some of which possess intrinsic surface-active or membrane-disruptive properties capable of damaging erythrocyte membranes.
Injectable TCM formulations represent the highest-risk category, since they are administered directly into the bloodstream where immediate contact with circulating erythrocytes occurs. Regulatory authorities in China, including requirements outlined in the Chinese Pharmacopoeia and the technical guidelines for TCM and natural drug injections, mandate hemolysis and erythrocyte aggregation testing before clinical trials, during formulation development, and as part of quality control for batch release. The test simultaneously evaluates two distinct phenomena: hemolysis, the lysis of red blood cells, and aggregation, the clumping of erythrocytes that may obstruct microcirculation.
Testing Samples
TCM Injections
FFinished and semi-finished injectable products derived from single herbs or compound formulas are the primary test subjects. These include solutions for intravenous and intramuscular administration, freeze-dried powders for injection reconstituted with the designated diluent, and large-volume infusion formulations containing TCM active fractions.
Intermediates and Extracts
Refined extracts, total fractions, and intermediate products used in the manufacturing chain are tested to characterize the hemolytic potential of each processing stage. This helps identify which purification steps reduce membrane-toxic impurities such as saponins or residual plant proteins before the final formulation is prepared.
New Drug Candidates and Purified Compounds
Natural product leads, purified marker compounds, and novel TCM-based formulations under preclinical investigation undergo hemolysis testing as part of the nonclinical safety package submitted for regulatory approval.
Compatibility and Stability Samples
Samples generated during compatibility studies with infusion solutions, as well as products stored under accelerated and long-term stability conditions, are evaluated to confirm that no hemolytic degradation products develop over the shelf life.
Testing Items
A comprehensive hemolysis evaluation for TCM products typically includes the following assessments:
- Visual hemolysis observation, detecting the transition of the test mixture to a clear red transparent solution indicating free hemoglobin release.
- Erythrocyte aggregation examination, observing whether red blood cells clump together and whether such clumps disperse upon gentle shaking.
- Quantitative hemolysis rate determination using spectrophotometry, calculating the percentage of hemolysis relative to complete-lysis and no-lysis controls.
- Sedimentation behavior monitoring, recording the settling of intact erythrocytes and the color and clarity of the supernatant at defined time points.
- Supplementary physicochemical characterization, including pH and osmolarity measurement of the test article, since hypotonicity and extreme pH can themselves induce hemolysis and confound interpretation.
Testing Methods
Visual Tube Method
The conventional method follows the hemolysis and aggregation procedure described in the Chinese Pharmacopoeia. Fresh rabbit blood is collected, defibrinated by stirring with glass rods, and washed repeatedly with physiological saline by centrifugation. A 2% red blood cell suspension is then prepared. A series of test tubes receives graded volumes of the test article together with physiological saline, followed by the erythrocyte suspension. A negative control tube contains only saline, while a positive control tube contains purified water to produce complete hemolysis.
All tubes are incubated at 37 degrees Celsius and inspected at defined intervals, commonly at half-hour observations over three to four hours. The analyst records whether hemolysis occurs, whether erythrocyte aggregates form, and whether any aggregates disperse after gentle agitation. The sample passes the test if no hemolysis and no irreversible aggregation are observed in the test tubes throughout the observation period.
Spectrophotometric Method
The improved quantitative method measures the absorbance of the supernatant at approximately 545 nanometers, corresponding to the absorption maximum of free hemoglobin. After incubation at 37 degrees Celsius, the tubes are centrifuged and the absorbance of each supernatant is compared against the positive control, which represents 100% hemolysis, and the negative control, which represents 0% hemolysis. The hemolysis rate is calculated from these values, and a result below 5% is generally regarded as acceptable, indicating no significant hemolytic activity.
Test System and Controls
Rabbit blood is the standard erythrocyte source, although human type O red blood cells may be used with scientific justification. Blood must be freshly collected and handled gently to avoid mechanical hemolysis during washing and resuspension. Test articles must be free of turbidity and visible particulates that would interfere with spectrophotometric readings; where necessary, the sample is centrifuged and the supernatant is used, with the step documented.
Result Interpretation
Interpretation integrates visual findings, quantitative hemolysis rates, and aggregation behavior. Borderline results between 5% and slightly higher values warrant repeat testing with refined sample preparation or an extended dilution series. A formulation that fails the test typically requires reformulation, additional purification to remove saponin-rich fractions, or adjustment of pH and tonicity.
Applications
Hemolysis testing supports TCM product development and regulation across multiple scenarios:
- Preclinical safety evaluation of new TCM injections prior to first-in-human clinical trials.
- Formulation screening and optimization, comparing candidate excipients, purification routes, and concentration limits for hemolytic constituents.
- Quality control and batch release testing for marketed injectable TCM products.
- Stability studies confirming that hemolytic degradation products do not emerge during storage.
- Investigation of adverse reaction reports, helping attribute clinical hemolysis-related events to product characteristics.
- Regulatory submissions to national drug authorities, where a compliant hemolysis report is a standard component of the safety dossier.
FAQ
What is the scientific principle of the TCM hemolysis test?
The test is based on the susceptibility of the erythrocyte membrane to damage by surface-active constituents. When saponins or similar compounds in a TCM preparation interact with the phospholipid bilayer of red blood cells, the membrane ruptures and intracellular hemoglobin escapes into the medium, which can be detected visually as a transparent red solution or quantified spectrophotometrically by absorbance near 545 nanometers.
Why is rabbit blood commonly used?
Rabbit erythrocytes exhibit sensitivity comparable to human cells, rabbits are a standard laboratory species for safety pharmacology, and regulatory guidance historically specifies rabbit blood, which ensures consistency and comparability of results across laboratories.
What is the acceptance criterion?
For the visual method, no hemolysis and no non-dispersible erythrocyte aggregation may appear during the observation period. For the spectrophotometric method, a hemolysis rate below 5% is the widely accepted threshold for judging the sample non-hemolytic.
Which TCM ingredients most often cause hemolysis?
Saponin-containing herbs and extracts, such as those rich in ginsenosides or similar glycosides, are the most frequent source of hemolytic activity, alongside certain tannins, proteins, and solubilizing excipients used at elevated concentrations.
How long does a standard test take?
A routine hemolysis assay, including blood collection, suspension preparation, incubation, and observation, is typically completed within one working day, while full report issuance including repeat or confirmatory runs may extend to several business days.